Collegium Pharmaceutical (NASDAQ:COLL) Downgraded to Hold Rating by Zacks Research

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $36.29 on Tuesday. Collegium Pharmaceutical has a 1-year low of $29.19 and a 1-year high of $50.79. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The firm has a market capitalization of $1.18 billion, a PE ratio of 17.79 and a beta of 0.73. The firm’s 50 day simple moving average is $34.78 and its 200 day simple moving average is $37.64.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.49 EPS. As a group, analysts expect that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in COLL. Group One Trading LLC bought a new stake in Collegium Pharmaceutical in the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 418 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of Collegium Pharmaceutical in the fourth quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.